Effects of Multiple Baricitinib (LY3009104) Doses on the Pharmacokinetics of a Cytochrome P450 3A Substrate, Simvastatin, in Healthy Subjects
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Baricitinib (Primary) ; Simvastatin
- Indications Cystic fibrosis; Diabetic cardiomyopathy; Diabetic nephropathies; Hypercholesterolaemia; Low HDL cholesterol; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 08 Jan 2014 Status changed from no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Oct 2013 New trial record